Anlotinib Recruiting Phase 2 Trials for refractory Small cell lung cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03823118S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer